Physician profile
Rodger Silverstein
NPI 1063418192
$1,014.31
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $106 · 2021: $141 · 2022: $423 · 2023: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $274.68 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $106.40 | 2022-2023 | Flarex |
| Allergan, INC. | $97.45 | 2019-2022 | |
| Alcon Vision LLC | $90.08 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $79.11 | 2022-2023 | Lotemax, Vyzulta, Lotemax Sm |
| Kala Pharmaceuticals, INC. | $70.90 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $70.73 | 2019-2021 | |
| Abbvie INC. | $64.83 | 2022-2023 | Durysta, Lumigan |
| Shire North American Group INC | $55.18 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.01 | 2019-2020 | |
| Sight Sciences, INC. | $39.54 | 2022-2023 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $24.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodger Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.